Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus CERETEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus CERETEC.
AN-DTPA vs CERETEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical